Production (Stage)
Galectin Therapeutics Inc.
GALT
$1.34
$0.021.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.05% | -10.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.46% | 37.08% | |||
| Operating Income | 36.46% | -37.08% | |||
| Income Before Tax | 19.52% | -6.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.52% | -6.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.52% | -6.66% | |||
| EBIT | 36.46% | -37.08% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 20.71% | -6.26% | |||
| Normalized Basic EPS | 20.13% | -5.86% | |||
| EPS Diluted | 20.71% | -6.26% | |||
| Normalized Diluted EPS | 20.13% | -5.86% | |||
| Average Basic Shares Outstanding | 0.73% | 0.75% | |||
| Average Diluted Shares Outstanding | 0.73% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||